Klaria Pharma (Sweden) Performance
| KLAR Stock | SEK 0.40 0.02 5.26% |
The company secures a Beta (Market Risk) of -1.82, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Klaria Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Klaria Pharma is expected to outperform it. Klaria Pharma Holding right now secures a risk of 7.94%. Please verify Klaria Pharma Holding downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to decide if Klaria Pharma Holding will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Klaria Pharma Holding has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Klaria Pharma is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 31.3 M |
Klaria |
Klaria Pharma Relative Risk vs. Return Landscape
If you would invest 48.00 in Klaria Pharma Holding on August 25, 2024 and sell it today you would lose (8.00) from holding Klaria Pharma Holding or give up 16.67% of portfolio value over 90 days. Klaria Pharma Holding is generating 0.0368% of daily returns and assumes 7.9396% volatility on return distribution over the 90 days horizon. Simply put, 70% of stocks are less volatile than Klaria, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Klaria Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Klaria Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Klaria Pharma Holding, and traders can use it to determine the average amount a Klaria Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0046
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KLAR |
Estimated Market Risk
| 7.94 actual daily | 70 70% of assets are less volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Klaria Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Klaria Pharma by adding Klaria Pharma to a well-diversified portfolio.
Klaria Pharma Fundamentals Growth
Klaria Stock prices reflect investors' perceptions of the future prospects and financial health of Klaria Pharma, and Klaria Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Klaria Stock performance.
| Return On Equity | -0.88 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (9.48) % | |||
| Current Valuation | 88.14 M | |||
| Shares Outstanding | 63.1 M | |||
| Price To Earning | (18.43) X | |||
| Price To Book | 1.42 X | |||
| Price To Sales | 8.00 X | |||
| EBITDA | (39.41 M) | |||
| Cash And Equivalents | 25.49 M | |||
| Cash Per Share | 0.47 X | |||
| Total Debt | 1.02 M | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (24.8 M) | |||
| Earnings Per Share | (1.72) X | |||
| Total Asset | 118.31 M | |||
| Retained Earnings | (9 M) | |||
| Current Asset | 44 M | |||
| Current Liabilities | 3 M | |||
About Klaria Pharma Performance
Assessing Klaria Pharma's fundamental ratios provides investors with valuable insights into Klaria Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Klaria Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Klaria Pharma Holding AB develops treatment methods in the therapeutic fields of migraine and pain related to cancer worldwide. Klaria Pharma Holding AB was founded in 2014 and is based in Uppsala, Sweden. Klaria Pharma is traded on Stockholm Stock Exchange in Sweden.Things to note about Klaria Pharma Holding performance evaluation
Checking the ongoing alerts about Klaria Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Klaria Pharma Holding help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Klaria Pharma had very high historical volatility over the last 90 days | |
| Klaria Pharma has some characteristics of a very speculative penny stock | |
| Klaria Pharma Holding has accumulated 1.02 M in total debt. Klaria Pharma Holding has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Klaria Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Klaria Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Klaria Pharma Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Klaria to invest in growth at high rates of return. When we think about Klaria Pharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (53.53 M) with profit before overhead, payroll, taxes, and interest of 5.87 M. | |
| Klaria Pharma Holding has accumulated about 25.49 M in cash with (24.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Klaria Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Klaria Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Klaria Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Klaria Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Klaria Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Klaria Pharma's stock. These opinions can provide insight into Klaria Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Klaria Stock Analysis
When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.